MNA
PLX icon

Manning & Napier Advisors’s Protalix BioTherapeutics PLX Stock Holding History

Manning & Napier Advisors’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-15,971
Closed -$784K – 345
2013
Q2 		$784K Buy
+15,971
New +$847K ﹤0.01% 312

Other funds holding PLX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Manning & Napier Advisors's PLX Position: Q3 2013 in Review

Manning & Napier Advisors sold out of Protalix BioTherapeutics (PLX) in Q3 2013, closing a stake of 15,971 shares — an estimated $784K sold.

Manning & Napier Advisors first reported a position in PLX in Q2 2013 and held it in 1 quarter. The position peaked at $784K in Q2 2013. 47 funds tracked by Wall St. Rank hold PLX as of Q3 2013.

  • Manning & Napier Advisors reported no remaining Protalix BioTherapeutics position as of Q3 2013 after selling out during the quarter.
  • Manning & Napier Advisors sold 15,971 Protalix BioTherapeutics shares in Q3 2013, an estimated $784K.
  • Manning & Napier Advisors first reported a position in Protalix BioTherapeutics in Q2 2013 and held it in 1 quarter.
  • Manning & Napier Advisors's Protalix BioTherapeutics position peaked at $784K in Q2 2013.
  • 47 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2013.

Based on Manning & Napier Advisors's 13F filing for Q3 2013, filed 18 Oct 2013.